Guest post: Congress shouldn ’t put future innovation at risk
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 29, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development Drug Cost Medicare Voters for Cures Source Type: news
Guest post: Congress should not put future innovation at risk
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 29, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development Drug Cost Medicare Voters for Cures Source Type: news
What is missing in the current drug pricing plan
A recentcongressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important reminder of how these middlemen operate in an opaque system that often leaves patients paying far more than they should for medicines. And it ’s also a reminder of what’s missing from the current drug pricing bill that passed in the House last week: (Source: The Catalyst)
Source: The Catalyst - November 23, 2021 Category: Pharmaceuticals Authors: Brian Newell Tags: Drug Cost Medicare Out-of-Pocket Costs Proactive Agenda Source Type: news
What ’s missing in the current drug pricing plan
Last week, acongressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important reminder of how these middlemen operate in an opaque system that often leaves patients paying far more than they should for medicines. And it ’s also a reminder of what’s missing from the current drug pricing bill that passed in the House last week: (Source: The Catalyst)
Source: The Catalyst - November 23, 2021 Category: Pharmaceuticals Authors: Brian Newell Tags: Drug Cost Medicare Out-of-Pocket Costs Proactive Agenda Source Type: news
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
According to our inauguralPatient Experience Survey (PES), insurance design can jeopardize patients ’ health due to access barriers to medicines. (Source: The Catalyst)
Source: The Catalyst - November 23, 2021 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Patients Out-of-Pocket Costs Polling Proactive Agenda Source Type: news
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
According to our inauguralPatient Experience Survey (PES), insurance design can jeopardize patients ’ health due to access barriers to medicines. (Source: The Catalyst)
Source: The Catalyst - November 23, 2021 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Patients Out-of-Pocket Costs Polling Proactive Agenda Source Type: news
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
As part of the annualSTAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke withSTAT’s Matthew Herperto discuss the many unintended consequences expected from the latest drug pricing plan on Capitol Hill, as well as the biopharmaceutical industry ’s plans to help build a better health care system that improves patient access and protects innovation. (Source: The Catalyst)
Source: The Catalyst - November 19, 2021 Category: Pharmaceuticals Tags: Drug Cost Medicare Out-of-Pocket Costs Polling Proactive Agenda Source Type: news
Making medicines more affordable: Sharing savings at the pharmacy counter
Common-sense reforms can help ensure everyone benefits from America ’s engine of innovation and receives the care they need and deserve. In thisseries, we ’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of ourpatient-centered agenda which aims to lower barriers between our industry’s medical innovations and patients who need them. (Source: The Catalyst)
Source: The Catalyst - November 19, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: Out-of-Pocket Costs Proactive Agenda Source Type: news
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract.Over the past 100 years, pandemics have been caused by novel forms of influenza and other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS) and Middle East Severe respiratory syndrome (MERS). Common complications of each of these infections include pneumonia which can lead to secondary bacterial infections requiring treatment with antibiotics. (Source: The Catalyst)
Source: The Catalyst - November 18, 2021 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Antimicrobial Resistance Source Type: news
Three things to know about so-called Medicare “negotiation” polling
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to educate voters on the policy arguments and trade-offs and consistently ignore voters ’true concerns, as well aspatient voices speaking out against these types of proposals. (Source: The Catalyst)
Source: The Catalyst - November 18, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Medicare Out-of-Pocket Costs Polling Proactive Agenda Source Type: news
Three things to know about so-called Medicare negotiation polling
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to educate voters on the policy arguments and trade-offs and consistently ignore voters ’true concerns, as well aspatient voices speaking out against these types of proposals. (Source: The Catalyst)
Source: The Catalyst - November 18, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Medicare Out-of-Pocket Costs Polling Proactive Agenda Source Type: news
In the current health care debate, Congress has lost sight of what matters to U.S. voters
For months Congress has been debating massive changes to the nation ’s social safety net, one of which is the highly popular Medicare prescription drug benefit. Unfortunately, much of what is being debated around that benefit today loses sight of the real barriers to a better health care system. It is a fact that too often, accessing medical treatment in the Unite d States is harder than it should be. Today,three in 10 Americans face financial barriers to care – and that’s Americanswith health insurance. Access hurdles exist throughout the health care system, including doctors ’ visits, hospitals, insurance premium...
Source: The Catalyst - November 15, 2021 Category: Pharmaceuticals Authors: Debra DeShong Tags: Drug Cost Medicare Proactive Agenda Source Type: news
Announcing CAREs Grant Round 4
Medicines can be critical to treating, managing, and sometimes curing illnesses, thereby offering an effective tool to improve health outcomes and reduce health disparities. However, numerous studies demonstrate that certain racially and ethnically diverse populations exhibit lower utilization of and adherence to medicines than their white counterparts.1,2,3 For example, even after accounting for socioeconomic status, Black and Hispanic insured Americans are 35% less likely to be adherent to medicines for diabetes or heart disease as compared to white Americans.4 (Source: The Catalyst)
Source: The Catalyst - November 12, 2021 Category: Pharmaceuticals Authors: Jackie McRae Tags: Health Equity Source Type: news
Making medicines more affordable: Modernizing Medicare
Common-sense reforms can help ensure everyone benefits from America ’s engine of innovation and receives the care they need and deserve. In this series, we ’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of our patient-centered agenda which aims to lower barriers between our industry’s medical innovations and patients who need them. (Source: The Catalyst)
Source: The Catalyst - November 11, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: Part D Medicare Part B Proactive Agenda Source Type: news
Making medicines more affordable: Modernizing Medicare
Common-sense reforms can help ensure everyone benefits from America ’s engine of innovation and receives the care they need and deserve. In this series, we ’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of our patient-centered agenda which aims to lower barriers between our industry’s medical innovations and patients who need them. (Source: The Catalyst)
Source: The Catalyst - November 11, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: Part D Medicare Part B Proactive Agenda Source Type: news
